196 related articles for article (PubMed ID: 31292915)
1. Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging.
Kanduluru AK; Srinivasarao M; Wayua C; Low PS
Mol Imaging Biol; 2020 Apr; 22(2):377-383. PubMed ID: 31292915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of a
Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM
Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of a Novel
Zhang H; Kanduluru AK; Desai P; Ahad A; Carlin S; Tandon N; Weber WA; Low PS
Bioconjug Chem; 2018 Apr; 29(4):1319-1326. PubMed ID: 29466853
[TBL] [Abstract][Full Text] [Related]
5. Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers.
Kanduluru AK; Low PS
Mol Pharm; 2017 Nov; 14(11):3859-3865. PubMed ID: 28969417
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of Re/
Radford LL; Papagiannopoulou D; Gallazzi F; Berendzen A; Watkinson L; Carmack T; Lewis MR; Jurisson SS; Hennkens HM
Bioorg Med Chem; 2019 Feb; 27(3):492-501. PubMed ID: 30594453
[TBL] [Abstract][Full Text] [Related]
8. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.
Abiraj K; Mansi R; Tamma ML; Forrer F; Cescato R; Reubi JC; Akyel KG; Maecke HR
Chemistry; 2010 Feb; 16(7):2115-24. PubMed ID: 20066690
[TBL] [Abstract][Full Text] [Related]
9. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Krall N; Pretto F; Mattarella M; Müller C; Neri D
J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
[TBL] [Abstract][Full Text] [Related]
10.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers.
Li G; Low PS
Bioorg Med Chem Lett; 2015 Apr; 25(8):1792-1798. PubMed ID: 25791453
[TBL] [Abstract][Full Text] [Related]
13.
Rezazadeh F; Sadeghzadeh N; Abedi SM; Abediankenari S
Nucl Med Biol; 2018; 62-63():54-62. PubMed ID: 29885559
[TBL] [Abstract][Full Text] [Related]
14. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
16. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
Li S; Beheshti M
Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
[TBL] [Abstract][Full Text] [Related]
17. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
18. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
19. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.
Schipper ML; Riese CGU; Seitz S; Weber A; Béhé M; Schurrat T; Schramm N; Keil B; Alfke H; Behr TM
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):638-650. PubMed ID: 17160413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
